Clinical Trials Logo

PPHN clinical trials

View clinical trials related to PPHN.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05527704 Recruiting - Respiratory Failure Clinical Trials

the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

REFSAL
Start date: December 31, 2021
Phase: Phase 3
Study type: Interventional

Clinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn (TTN).